Product Information
Registration Status: ActiveSIN02613P
RHINATHIOL PROMETHAZINE SYRUP is approved to be sold in Singapore with effective from 1989-04-21. It is marketed by SANOFI-AVENTIS SINGAPORE PTE LTD, with the registration number of SIN02613P.
This product contains Carbocisteine 2g/100ml, and Promethazine 0.05g/100ml in the form of SYRUP. It is approved for ORAL use.
This product is manufactured by Unither Liquid Manufacturing in FRANCE.
It is a Pharmacy Only Medicine that can be obtained from a pharmacist at a retail pharmacy.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Carbocisteine is a mucolytic that reduces the viscosity of sputum and so can be used to help relieve the symptoms of chronic obstructive pulmonary disorder (COPD) and bronchiectasis by allowing the sufferer to bring up sputum more easily. Carbocisteine should not be used with antitussives (cough suppressants) or medicines that dry up bronchial secretions. Carbocisteine is produced by alkylation of cysteine with chloroacetic acid.
Indication
Used to help relieve the symptoms of chronic obstructive pulmonary disorder (COPD) and bronchiectasis.
Active Ingredient/Synonyms
(L)-2-Amino-3-(carboxymethylthio)propionic acid | (R)-S-(carboxymethyl)cysteine | L-3-((carboxymethyl)thio)alanine | L-carbocysteine | S-(carboxymethyl)-(R)-cysteine | S-carboxymethyl-L-cysteine | S-carboxymethylcysteine | Carbocisteine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.
Description
A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals. [PubChem]
Indication
For the treatment of allergic disorders, and nausea/vomiting.
Mechanism of Action
Like other H1-antagonists, promethazine competes with free histamine for binding at H1-receptor sites in the GI tract, uterus, large blood vessels, and bronchial muscle. The relief of nausea appears to be related to central anticholinergic actions and may implicate activity on the medullary chemoreceptor trigger zone.
Pharmacokinetics
- Absorption
- On average, 88% of a promethazine dose is absorbed after oral administration; however, the absolute bioavailability is only 25% because of first-pass clearance.
- Distribution
- Metabolism
- Hepatic
- Elimination
Toxicity
Symptoms of overdose include mild depression of the central nervous system and cardiovascular system to profound hypotension, respiratory depression, unconsciousness, and sudden death. Other reported reactions include hyperreflexia, hypertonia, ataxia, athetosis, and extensor-plantar reflexes (Babinski reflex). LD50=55mg/kg (I.V. in mice)
Active Ingredient/Synonyms
(2-dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine | 10-(2-Dimethylaminopropyl)phenothiazine | 10-[2-(dimethylamino)Propyl]phenothiazine | N-(2'-dimethylamino-2'-Methyl)ethylphenothiazine | N,N,alpha-Trimethyl-10H-phenothiazine-10-ethanamine | N,N,α-trimethyl-10H-phenothiazine-10-ethanamine | Proazamine | Prometazina | Promethazine | Promethazinum | Promethazine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.